Welcome to our dedicated page for Altamira Therapeutics news (Ticker: CYTOF), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics stock.
Altamira Therapeutics Ltd (CYTOF) is a biotechnology company focused on peptide-based nanoparticle technologies for nucleic acid and RNA delivery. Company news and press releases highlight developments around its xPhore™ platform, internal RNA programs, and legacy assets in allergy and inner ear disorders.
Readers following CYTOF news can expect updates on RNA and DNA delivery technology, including new data from in vitro and in vivo studies, expansion of the xPhore platform to modalities such as siRNA, mRNA, circular RNA, and DNA, and the introduction of sub-platforms like OligoPhore™, SemaPhore™, CycloPhore™, and GenePhore™. Altamira also reports on collaboration agreements with biotech and pharma partners who evaluate these platforms for applications such as mRNA vaccines, radiopharmaceutical cancer therapies, and circular RNA-based drugs.
Another recurring theme in Altamira’s news is progress with its legacy portfolio. This includes regulatory and commercial milestones for Bentrio®, an over-the-counter, drug-free nasal spray for allergic rhinitis owned by its associate Altamira Medica AG. Recent announcements have covered certification of Bentrio under the EU Medical Device Regulation, marketing approval in Mainland China, and patent protection steps in the United States. News items also address intellectual property developments for AM-125, an intranasal betahistine program for acute vestibular syndrome.
Altamira’s releases further provide business updates and financial results, including information on operating expenses, research and development focus, and plans to partially spin off its RNA delivery subsidiary to private equity investors. Investors and observers who monitor CYTOF news can use this page to track technology progress, partnering activity, regulatory milestones, and strategic corporate moves over time.
Altamira Therapeutics (OTCID:CYTOF) said its associate Altamira Medica received a Japan Patent Office notice of allowance for a patent covering Bentrio® nasal spray.
Bentrio is described as a drug‑free, preservative‑free medical device, approved or cleared in several countries for prophylaxis and treatment of allergic rhinitis, with clinical data supporting safety and efficacy.
Altamira Therapeutics (OTCID:CYTOF) will present at the 5th mRNA-Based Therapeutics Summit Europe on January 28-29, 2026 in Berlin. Covadonga Pañeda, Ph.D., Chief Operating Officer, will present "CycloPhore & SemaPhore enabling next-generation delivery solutions for circular RNA & mRNA therapeutics." The company described differences between linear mRNA (faster onset, controllable, transient expression) and circular RNA (longer or enhanced expression, reduced dosing) and positioned its CycloPhore and SemaPhore platforms as delivery technologies designed to maximize each modality's advantages for acute and chronic indications.
Altamira Therapeutics (OTCID:CYTOF) announced that associate Altamira Medica received NMPA marketing approval in Mainland China for Bentrio® nasal spray in allergic rhinitis on December 19, 2025. The clearance permits partner Nuance Pharma to market and distribute Bentrio across Mainland China. Epidemiological estimates cited in the announcement put the potential addressable population at ~200 million people with allergic rhinitis. The company highlighted Bentrio's preservative-free formulation and a triple mode of action, and said trials showed efficacy and good tolerability. The announcement frames the approval as a commercial milestone and the start of a China launch by Nuance Pharma.
Altamira Therapeutics (OTCQB:CYTOF) announced on November 20, 2025 that associate Altamira Medica obtained EU Medical Device Regulation (MDR) certification for Bentrio nasal spray. The certification confirms conformity with the EU's stricter safety, performance and quality requirements for medical devices and is a prerequisite for legally commercializing Bentrio in EU member states.
The announcement notes Bentrio was previously launched under the MDD as a Class I device in 2021 and was up‑classified to Class IIa under MDR, which required clinical trials, independent Notified Body certification and substantial investments by Medica. The company says MDR status also supports regulatory filings outside the EU and aids the product's international growth strategy.
Altamira Therapeutics (OTCQB:CYTOF) announced on November 3, 2025 that its peptide‑based nanoparticle platform xPhore successfully delivered DNA molecules in vitro, producing efficient cell transfection and reliable protein expression.
Altamira will offer the DNA delivery capability under the GenePhore label, complementing existing offerings for short RNA (OligoPhore), linear mRNA (SemaPhore) and circular RNA (CycloPhore).
The company said GenePhore could support applications including DNA vaccines, gene editing, and protein replacement therapies. The announcement cites independent research estimating the global gene delivery technologies market at $5.35 billion in 2024 and projecting growth to $22.8 billion by 2034.
Altamira Therapeutics (OTCQB:CYTOF) reported its first half 2025 financial results and business updates, highlighting progress in its RNA delivery technology business. The company's operating loss decreased by 32.9% to $2.6 million, while net loss reduced by 64.6% to $1.5 million compared to H1 2024.
Key developments include securing two new collaboration partners for evaluating xPhore platform technology, including CycloPhore for circular RNA delivery. The company is advancing plans for a partial spin-off of its RNA delivery business through its Swiss subsidiary ATAG, while reducing operating expenses. Cash and cash equivalents stood at $4,000 as of June 30, 2025, down from $1.0 million at year-end 2024.
Progress was also reported in legacy assets, including Bentrio® nasal spray's transition to Class IIa medical device status in the EU and expanded patent coverage for AM-125 in over 50 countries.
[ "Operating loss decreased 32.9% to $2.6 million in H1 2025", "Net loss reduced significantly by 64.6% to $1.5 million", "Cash used in operations decreased by 56.8% to $1.4 million", "Secured two new RNA delivery collaboration partners in 2025", "Expanded patent coverage for AM-125 to over 50 countries" ]Altamira Therapeutics (OTCQB:CYTOF), focused on RNA delivery technology development beyond liver applications, has scheduled its First Half 2025 Financial Results and Business Update Call for August 29, 2025, at 8:00 am ET.
The conference call will feature prepared remarks from Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda. The event will be accessible via toll-free and international dial-in numbers, with a webcast option available. A replay will be accessible 30 minutes after the live event through September 12, 2025.
Altamira Therapeutics (OTCQB:CYTOF) has received allowance for its Japanese patent application covering intranasal betahistine formulations and methods of use. The patent specifically covers the company's AM-125 nasal spray program, which is designed to treat dizziness.
The Japan Patent Office Board of Appeals' decision strengthens Altamira's intellectual property portfolio, which now includes patent coverage for AM-125 in more than 50 countries, including major markets in North America and Europe. The company plans to commercialize AM-125 through strategic partnerships to address the needs of patients suffering from dizziness.
Altamira Therapeutics (OTCQB:CYTOF) has entered into a collaboration agreement with an undisclosed company to evaluate its CycloPhore™ platform for circular RNA payload delivery. The partnership involves testing CycloPhore nanoparticles both in vitro and in vivo, with the partner having an option to negotiate a license agreement for developing and commercializing circRNA nanoparticles with their proprietary RNA payload.
The collaboration marks the first partnership for Altamira's recently launched CycloPhore platform, specifically designed for circular RNA delivery. According to COO Covadonga Pañeda, circular mRNA could enable lower dosing and less frequent administrations compared to linear mRNA, representing a promising approach in RNA drug development.
Altamira Therapeutics reported its full year 2024 financial results, highlighting significant progress in its RNA delivery business. The company's xPhore platform demonstrated successful testing with circular RNA, showing higher protein expression compared to linear mRNA. Operating loss from continuing operations increased slightly to $6.9 million, while cash used in operations decreased by more than half to $6.1 million.
Key developments include:
- Plans to partially spin off RNA delivery business to private equity investors
- Successful testing of xPhore platform with circular RNA
- New collaborations with Univercells Group for mRNA vaccines and an undisclosed radiopharmaceutical partner
- Year-end cash position of $1.0 million, up from $0.7 million in 2023
- Shareholders' equity of $6.6 million, down from $7.7 million in 2023
The company expects to sign at least two more partnerships in 2025 and plans to reduce operating expenses following the planned partial spin-off of its ATAG subsidiary.